Sponsor
Akeso
Clinical research sponsor
How to interpret these research links
Connected source recordsThe exact organization name Akeso appears in 34 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
34 shownA Phase II Study of AK146D1 Combined With AK112 in Advanced Breast CancerNCT07591090 · lead sponsor · 2026-07-17
RECRUITINGA Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung CancerNCT07669779 · lead sponsor · 2026-07-10
RECRUITINGA Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung CancerNCT07623356 · lead sponsor · 2026-07-07
RECRUITINGA Study of Ivonescimab in First-Line ES-SCLCNCT07245446 · lead sponsor · 2025-10-29
RECRUITINGIvonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung CancerNCT06928389 · lead sponsor · 2025-07-08
RECRUITINGA Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation TherapyNCT07010263 · lead sponsor · 2025-06-13
RECRUITINGAK129 Combination Therapy for Advanced Solid TumorsNCT06943820 · lead sponsor · 2025-05-21
RECRUITINGAK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast CancerNCT06767527 · lead sponsor · 2025-02-07
RECRUITINGA Study of AK104 in Subjects With Unresectable Locally Advanced NSCLCNCT06617416 · lead sponsor · 2024-11-12
RECRUITINGA Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Breast CancerNCT07560124 · lead sponsor · 2026-06-06
NOT_YET_RECRUITINGA Study to Evaluate the Efficacy and Safety of AK139 in Participants With AsthmaNCT07436221 · lead sponsor · 2026-02-28
NOT_YET_RECRUITINGA Clinical Trial of AK152 in Healthy Volunteers and Patients With Alzheimer' s DiseaseNCT07301502 · lead sponsor · 2025-12-01
NOT_YET_RECRUITINGAK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase Inhibitor (TKI) TreatmentNCT07158840 · lead sponsor · 2025-09-05
NOT_YET_RECRUITINGA Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung CancerNCT05990127 · lead sponsor · 2023-11-14
NOT_YET_RECRUITINGAK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung CancerNCT05840016 · lead sponsor · 2023-08-17
ACTIVE_NOT_RECRUITINGAK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung CancerNCT05904379 · lead sponsor · 2023-07-13
ACTIVE_NOT_RECRUITINGStudy of AK119 and AK112 With or Without Chemotherapy for NSCLC PatientsNCT05636267 · lead sponsor · 2023-02-10
TERMINATEDAK112 in Advanced Non-Small Cell Lung CancerNCT05499390 · lead sponsor · 2022-11-09
ACTIVE_NOT_RECRUITINGA Study of AK104 in Combination With Chiauranib in Patients With Extensive Stage Small Cell Lung CancerNCT05505825 · lead sponsor · 2022-08-26
COMPLETEDA Phase II Trial of AK104 in Advanced Non-Small Cell Lung CancerNCT05215067 · lead sponsor · 2022-05-13
COMPLETEDA Study of AK117/AK112 in Metastatic Triple-Negative Breast CancerNCT05227664 · lead sponsor · 2022-03-23
ACTIVE_NOT_RECRUITINGAK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLCNCT05247684 · lead sponsor · 2022-02-20
ACTIVE_NOT_RECRUITINGA Study to Evaluate the Efficacy and Safety of AK120 in the Treatment of Subjects With Moderate-to-severe AsthmaNCT05155020 · lead sponsor · 2022-02-11
TERMINATEDPhase 3 Clinical Study of AK112 for NSCLC PatientsNCT05184712 · lead sponsor · 2022-01-25
ACTIVE_NOT_RECRUITINGA Trial of AK112 (PD-1/VEGF Bispecific Antibody) in Patients With NSCLCNCT04900363 · lead sponsor · 2021-05-21
COMPLETEDA Study of AK104（ an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical CancerNCT04868708 · lead sponsor · 2021-04-01
COMPLETEDAnti-PD-1 and VEGF Bispecific Antibody AK112 in Combination With Chemotherapy in Patients With ES-SCLCNCT05116007 · lead sponsor · 2021-03-29
COMPLETEDA Study of AK104 in Patients With Locally Advanced or Metastatic Non-small Cell Lung CancerNCT04647344 · lead sponsor · 2020-11-24
COMPLETEDA Study to Evaluate the Efficacy and Safety of Anti-PD-1 Antibody AK105 in Patients With Selected Advanced Solid TumorsNCT04172506 · lead sponsor · 2019-09-10
COMPLETEDA Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, for Advanced Solid Tumors or With mXELOX/XELOX as First-line Therapy for Advanced Gastric or GEJ AdenocarcinomaNCT03852251 · lead sponsor · 2019-01-18
COMPLETEDA Study of Anti-PD-1 AK105 in Patients With Metastatic Squamous Non-small Cell Lung CancerNCT03866993 · lead sponsor · 2018-12-20
COMPLETEDA Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung CancerNCT03866980 · lead sponsor · 2018-11-27
TERMINATEDctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)NCT06951646 · collaborator · 2026-03-10
RECRUITINGPhase III Study of AK112 for NSCLC PatientsNCT06396065 · collaborator · 2023-05-04
ACTIVE_NOT_RECRUITINGSponsor roles
lead sponsor32
collaborator2
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.